Literature DB >> 8717104

The levels of memory (CD45RA-, RO+) CD4+ and CD8+ peripheral blood T-lymphocytes correlate with IgM rheumatoid factors in rheumatoid arthritis.

M Neidhart1, K Fehr, F Pataki, B A Michel.   

Abstract

We investigated whether, in rheumatoid arthritis (RA), the CD45 isoform expression of peripheral blood T-lymphocytes (T-PBL) is related to auto-immune processes (e.g. IgM rheumatoid factors) and to clinical manifestations. By three-colour flow cytometry, we quantified three subsets of CD4+ or CD8+ T-PBL: "naive" CD45RA+,RO-, "transient" CD45RA+,RO+, and "memory" CD45RA-,RO+ cells, in 102 patients with RA and in 41 age- and sex-matched controls. The serum levels of rheumatoid factors (RF) were determined--besides conventional agglutination tests--by ELISA (IgM-RF). Extensive clinical examination was performed at the time of blood sampling. In RA, age, sex and drug therapy did not constitute major influences on the CD45RA/RO patterns. In "healthy" men, higher age significantly' correlated with fewer naive and more memory CD4+ T-PBL (P < 0.01). In RA, distinct correlations between the T-PBL subsets, autoimmune and clinical manifestations became obvious when patients with low and high levels of RF against human IgG Fc fragments, as determined by ELISA, were analysed separately. RA patients with high IgM-RF had elevated proportions of CD45RO+ T-PBL (P < 0.05), that correlated with clinical parameters of disease activity (tender joint count, Ritchie index, P < 0.05) and outcome (Health Assessment Questionnaire, Larsen radiographic scores, P < 0.05). The proportions of memory CD4+ and CD8+ T-PBL correlated strongly (P < 0.001) with the IgM-RF levels. Within 1 year, only three of 34 patients (disease duration of 5-9 years) showed seroconversion from low to high levels of IgM-RF (and positive agglutination tests); this was paralleled by reductions in naive and increases in transient T-PBL (P < 0.02). Thus, in RA, the proportions of memory CD4+ and CD8+ T-PBL correlate with the level of IgM-RF and, together with transient T-PBL, with clinical parameters of disease activity and outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717104     DOI: 10.1007/BF00290522

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

1.  Immune imbalance in the synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin.

Authors:  A Afeltra; M Galeazzi; P Basso; A Pietrucci; O De Pità; G M Ferri; F Porzio; L Bonomo
Journal:  J Biol Regul Homeost Agents       Date:  1991 Apr-Jun       Impact factor: 1.711

2.  Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells.

Authors:  D L Wallace; P C Beverley
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

3.  Functional characterization of the CD45R (2H4) molecule on CD8 (T8) cells in the autologous mixed lymphocyte reaction system.

Authors:  T Takeuchi; C E Rudd; S Tanaka; D M Rothstein; S F Schlossman; C Morimoto
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

4.  [Rheumatoid factor test by a simple hemagglutination-drop-test (Rheumatontest). Comparison with Waaler-Rose and 2 latex tests].

Authors:  K Fehr; A Böni
Journal:  Schweiz Rundsch Med Prax       Date:  1972-08-29

5.  A simple enzyme immunoassay for the demonstration of rheumatoid factor.

Authors:  M Gripenberg; F Wafin; H Isomäki; E Linder
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

6.  Phenotypic diversity of the CD45 antigen and its relationship to function.

Authors:  P C Beverley; M Merkenschlager; L Terry
Journal:  Immunol Suppl       Date:  1988

7.  Sulfasalazine therapy in psoriatic arthritis: clinical and immunologic response.

Authors:  E D Newman; J L Perruquet; T M Harrington
Journal:  J Rheumatol       Date:  1991-09       Impact factor: 4.666

8.  Lymphocyte surface marker expression in rheumatic diseases: evidence for prior activation of lymphocytes in vivo.

Authors:  M D Smith; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

9.  The immunoregulation of rheumatoid factor by the CD8 T lymphocyte subset in rheumatoid arthritis.

Authors:  I al-Azem; F Fernandez-Madrid; P M Long; P H Wooley
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

10.  Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population.

Authors:  P De Paoli; S Battistin; G F Santini
Journal:  Clin Immunol Immunopathol       Date:  1988-09
View more
  8 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Authors:  R L Van Bezooijen; L Van Der Wee-Pals; S E Papapoulos; C W G M Löwik
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

3.  Flow cytometric characterisation of the "false naive" (CD45RA+, CD45RO-, CD29 bright+) peripheral blood T-lymphocytes in health and in rheumatoid arthritis.

Authors:  M Neidhart; F Pataki; J Schönbächler; P Brühlmann
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission.

Authors:  Martina Prelog; Nora Schwarzenbrunner; Elisabeth Tengg; Michaela Sailer-Höck; Hannelore Kern; Lothar Bernd Zimmerhackl; Juergen Brunner
Journal:  Clin Rheumatol       Date:  2008-12-18       Impact factor: 2.980

5.  The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treament.

Authors:  Jorge Monserrat; Cristina Bohórquez; Ana María Gómez Lahoz; Atusa Movasat; Ana Pérez; Lucía Ruíz; David Díaz; Luis Chara; Ana Isabel Sánchez; Fernando Albarrán; Ignacio Sanz; Melchor Álvarez-Mon
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

6.  Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment.

Authors:  Asma Khanniche; Ling Zhou; Bin Jiang; Jing Song; Yanhua Jin; Jian Yin; Shujun Wang; Ping Ji; Hao Shen; Ying Wang; Huji Xu
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

7.  A critical epitope in CD147 facilitates memory CD4+ T-cell hyper-activation in rheumatoid arthritis.

Authors:  Na Guo; Sheng Ye; Kui Zhang; Xiaoling Yu; Hongyong Cui; Xiangmin Yang; Peng Lin; Minghua Lv; Jinlin Miao; Yang Zhang; Qing Han; Rongguang Zhang; Zhinan Chen; Ping Zhu
Journal:  Cell Mol Immunol       Date:  2018-03-21       Impact factor: 11.530

8.  Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients.

Authors:  Jorge Monserrat Sanz; Cristina Bohórquez; Ana Maria Gómez; Atusa Movasat; Ana Pérez; Lucía Ruíz; David Diaz; Ana Isabel Sánchez; Fernando Albarrán; Ignacio Sanz; Melchor Álvarez-Mon
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.